A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Recruiting

Phase 1

Phase 2

SP-101A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Sponsor:

Spirovant Sciences, Inc.

Code:

NCT06526923

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

SP-101 and doxorubicin Cohort 1

SP-101 and doxorubicin Cohort 2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-03. This information was provided to ClinicalTrials.gov by Spirovant Sciences, Inc. on 2024-11-25.